Clinical Trials

60 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00574730 2023-09-14

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Phase NA Completed

27 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

9 enrolled 9 charts

Neurofibroma, Neurofibromatosis 1

NCT00049530 2023-06-29

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

32 enrolled 8 charts

Melanoma

NCT00134030 2023-06-07

EURAMOS-1

Other hematologic neoplasm

1,334 enrolled 17 charts

Sarcoma

Osteosarcoma

NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Phase 2/3 Completed

30 enrolled

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

8 enrolled 11 charts

DermatologicGenitourinary

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

NCT02089685 2022-09-13

MK-3475-029

Phase 1/2 Completed

295 enrolled 25 charts

Carcinoma, Renal Cell, Melanoma

NCT01387763 2022-04-27

DALIAH

202 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02343224 2022-01-24

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

9 enrolled 12 charts

Astrocytoma

NCT02112032 2021-05-05

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

43 enrolled

Melanoma

NCT00525031 2020-09-23

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

55 enrolled 7 charts

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT03554005 2019-07-15

MK-4031-009

29 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT01933906 2019-01-04

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

12 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02155322 2018-08-23

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

33 enrolled 7 charts

Melanoma

NCT00014261 2018-03-30

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00396019 2017-11-06

Study of PEG-Intron for Plexiform Neurofibromas

86 enrolled 6 charts

Neurofibroma, Plexiform

NCT00457418 2017-06-07

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

32 enrolled 12 charts

Melanoma

NCT01496807 2017-04-28

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

31 enrolled 11 charts

Melanoma

NCT00759109 2017-04-07

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

150 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00861406 2017-03-03

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

38 enrolled

Melanoma

NCT01949805 2016-11-28

PROUD-PV

257 enrolled

Myeloid

Polycythemia Vera

NCT00548847 2016-10-26

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Other hematologic neoplasm

15 enrolled 9 charts

Leukemia

NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

94 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00303290 2015-11-26

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

76 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00045279 2013-06-05

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00238329 2013-04-08

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

32 enrolled

Uveal Melanoma, Melanoma

NCT00055809 2013-01-23

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

EndocrineGastrointestinal

44 enrolled

Metastatic Gastrointestinal Carcinoid Tumor

NCT00276523 2012-10-31

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

3 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00047879 2011-10-26

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

7 enrolled 8 charts

Brain Neoplasms, Glioma

NCT00623402 2011-01-12

SoraPeg

55 enrolled

Melanoma

NCT01227356 2010-10-25

A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia

112 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00221702 2010-10-13

EADO

898 enrolled